Table 3

GI end points

Celecoxib

(n = 28,614)

nsNSAID

(n = 15,278)

Placebo

(n = 5,827)

Rofecoxib

(n = 1,329)

Total

(n = 51,048)


CSULGIEs, n (%)

37 (0.1)

40 (0.3)

12 (0.2)

0 (0)

89 (0.2)


Incidence ratea

0.3

0.9

0.3

0

0.4


CSULGIEs or symptomatic ulcers, n (%)

47 (0.2)

44 (0.3)

12 (0.2)

0 (0)

103 (0.2)


Incidence ratea

0.4

1.0

0.3

0

0.5


CSULGIEs, symptomatic ulcers, or hemoglobin decrease, n (%)

281 (1.0)

343 (2.3)

52 (0.9)

4 (0.3)

680 (1.3)


Incidence ratea

2.3

7.4

1.4

2.6

3.3


aIncidence rate based on 100 patient-years of exposure to drug. CSULGIEs, clinically significant upper and lower GI events; nsNSAID, nonselective nonsteroidal antiinflammatory drug.

Moore et al. Arthritis Research & Therapy 2013 15:R6   doi:10.1186/ar4134

Open Data